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Serum Interleukin-18 Expression in Children With
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Background: Interleukin 18 (IL-18) is reported to have regulatory
functions on Th1 and Th2 cytokine production and proinflammatory
effects through promoting recruitment of memory Th1 cells to
inflammatory sites. We sought to investigate the expression of the
serum IL-18 in childhood bronchial asthma in relation to disease
activity and severity.
Methods: Serum IL-18 was measured by enzymatic immunoassay
in 25 asthmatic children during exacerbation and after complete
quiescence of symptoms and signs. The results were compared to
those of 35 nonallergic age- and sex-matched children.
Results: Serum IL-18 levels during asthma exacerbation [median 
125 pg/mL; mean (SD)  128.6 (43.3) pg/mL] were significantly
lower than the follow-up levels during stability [median  250
pg/mL; mean (SD) 291.6 (66.7) pg/mL] and both levels correlated
positively with each other. The corresponding values of the control
group were higher than those of the asthmatic patients whether
during exacerbation or stability [median  380 pg/mL; mean
(SD)  476.1 (259.6) pg/mL]. The serum IL-18 concentrations did
not vary significantly according to asthma severity, family history of
atopy, or passive smoking. The influence of inhaled corticosteroids
on IL-18 expression was not impressive and neither was the relation
between serum IL-18 and the peripheral blood eosinophil count or
serum total IgE expression.
Conclusions: Serum IL-18 was found underexpressed in a group of
asthmatic children especially during exacerbation. Further studies
are needed to outline its exact role in the pathogenesis of asthma.
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Interleukin-18 is a pleiotrophic cytokine involved in bothTh1 and Th2 differentiation.1 It is predominantly produced
by activated macrophages and synergizes with IL-12 and IL-2
to induce IFN- synthesis, thereby promoting Th1 cytokine
response.2,3 It was hypothesized that reduced IFN- secretion
in the presence of increased secretion of IL-18 may imply a
defect in IL-18 responsiveness in allergic patients.4 It was
reported that a deficiency of IFN- production in severe
atopic dermatitis (AD) patients could not be reversed by
IL-18 in vitro.5
IL-18 may stimulate Th1 cells in vivo to produce also
IL-13, granulocyte-macrophage colony stimulating factor,
and IL-8, which in combination might induce severe inflam-
mation.6 IL-18 has chemotactic activities in vitro and in vivo
operating in particular upon human Thl cells. Thus, in addi-
tion to its activities in functional regulation of naive T cell
differentiation, it may have an important role in promoting
recruitment of memory Thl cells to an inflammatory lesion.7
It may possess some other biologic properties including
upregulation of intercellular adhesion molecule-1 and Fas
ligand in human myelomonocytic cells.8,9
Paradoxically, IL-18, by itself, strongly induces IgE
and allergic inflammation, indicating a role for IL-18 in
promoting Th2 response.3 Although IL-18 was initially
thought to negatively regulate CD4 cell-derived IL-4 syn-
thesis, via an IFN- independent mechanism, thereby limiting
the development of type 2 immune responses,10 later studies
revealed its potential to induce Th2 cytokine production from
T cells, NK cells, and basophils/mast cells.6 It seems that
IL-18 has the ability to promote both Th1 and Th2 responses,
depending on the surrounding cytokine environment.11
IL-18 was found to induce allergic inflammation in a
mouse model and its role in AD in particular has been
outlined. Depletion of IL-18 was found to rescue the mice
from AD, indicating IL-18-dependent, Th2-independent AD.
This type of AD was classified as innate-type allergy in
contrast to Th2 cell-dependent ordinary allergy. It may be
categorized as Th1-associated allergy and it would be inter-
esting to evaluate whether individual allergic disorders in-
volve either of these IL-18-mediated pathways or a Th2-
mediated one.12 The functional role of IL-18-induced “innate
allergic response” was also explained in the context of host
defense against gastrointestinal nematode infection by acti-
vating intestinal mucosal mast cells in a Th2-independent
manner.13
This background stimulated our study of the IL-18
expression in the serum of children with bronchial asthma
during and after subsidence of exacerbations in relation to
severity and other disease traits.
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METHODS
Study Population
This follow-up study comprised 25 asthmatic and 35
healthy children. The asthmatic children were enrolled con-
secutively from the Pediatric Allergy and Immunology Unit
of the Children’s Hospital in Cairo, Egypt during an acute
asthma exacerbation. The diagnosis of asthma was estab-
lished according to the American Thoracic Society criteria.14
There were 16 boys and 9 girls. Their ages ranged from 2.5
to 11.5 years with a median age of 8 (mean  8  3 years).
The patients were classified according to severity of exacer-
bation into 5 children with mild, 5 with moderate, and 15 with
severe exacerbation and were classified during stability into 7
patients with mild persistent, 14 with moderate persistent, and
4 with severe persistent asthma.15 At time of initial sampling,
17 children (68%) were compliant on regular corticosteroid
inhalation therapy (fluticasone propionate 100–250 g/day)
whereas 8 children (32%) were not receiving corticosteroids.
Their chest radiographs were normal and cases with concom-
itant illness were excluded from the study. The patients were
subjected to the study measurements at enrollment and were
followed up to be re-evaluated after clinical subsidence of
symptoms and signs.
The control group comprised 35 healthy children (22
boys and 13 girls). Their ages ranged from 2 to 10.5 years
(median  6.5 years; mean  6.5  2.5 years). They had no
present, past, or family history suggestive of allergy. An
informed consent was obtained from the parents or caregivers
of each subject before enrollment and the study protocol
gained approval from the ethics committee of the Department
of Pediatrics, Ain Shams University.
Study Measurements
Five milliliters of blood was aseptically collected in
aliquots by venepuncture from each subject in sterile tubes
for blood cell counting and serum Il-18 and total IgE assays.
The serum was separated by centrifugation at 1500 rpm for
15 minutes after 2 hours of incubation at 25°C and was stored
at 20°C until assayed.
Serum IL-18 level
The serum IL-18 level was quantitatively estimated
using a human IL-18 immunoassay (Bender MedSystems
GmbH, Campus Vienna Biocenter 2, A-1030 Vienna, Aus-
tria) according to the manufacturer’s instructions. The assay
employs the quantitative sandwich enzyme immunoassay
technique.
Serum total IgE
The serum total IgE was measured by ELISA (Gen-
zyme Diagnostics, Medix Biotech, San Carlos, Calif). A
serum IgE level was considered elevated if it exceeded the
highest reference value for age.16 The value used in correla-
tion analysis was the percentage from the highest normal for
age (patient’s actual level divided by the highest reference
value for age multiplied by 100). Subjects in the control
group with elevated serum total IgE levels were excluded
from the study.
Complete blood counting
Complete blood counting was performed with use of a
cell counter (Coulter MicroDiff 18, Fullerton, Calif) and by
manual differential. Blood sampling of all subjects was per-
formed at the same time daily (10 AM) to avoid diurnal
variation of eosinophil count.
Statistical Analysis
The results were statistically analyzed via a standard
computer program (SPSS version 10 for Windows, Chi-
cago, Ill). The data are expressed as median, interquartile
range, mean, and SD. For analysis of the nonparametric
data, Mann-Whitney U test, Wilcoxon signed rank test,
and Kruskal-Wallis tests were used. A multivariate analy-
sis employing multiple linear regression was used to relate
the magnitude of the drop in serum IL-18 (“delta”) to other
data of the patients using the analysis of variance test.
Correlations were evaluated by the Spearman’s rank cor-
relation coefficient. For all tests, P values less than 0.05
were considered significant.
RESULTS
Serum IL-18 levels during asthma exacerbations ranged
from 65 to 200 pg/mL [median  125 pg/mL; mean (SD) 
128.6 (43.3) pg/mL]. These values were significantly lower
than those of the same patients when studied after subsidence
of symptoms and signs [range  100–370 pg/mL; median 
250 pg/mL; mean (SD)  241.6 (66.7) pg/mL]. The healthy
children had significantly higher serum IL-18 levels [range
190–1150 pg/mL; median 380 pg/mL; mean (SD) 476.1
(259.6) pg/mL] compared with the patients’ levels whether
during exacerbation or stability (Figs. 1, 2).
The serum IL-18 expression did not vary significantly
with the severity of exacerbation. Levels of patients with mild
attacks ranged from 66 to 200 pg/mL [median  100 pg/mL;
mean (SD)  124.2 (53.0) pg/mL]. The corresponding levels
during moderate and severe attacks ranged from 68 to 195
pg/mL [median  100 pg/mL; mean (SD)  121.6 (50.6)
pg/mL] and from 65 to 200 pg/mL [median  125 pg/mL;
mean (SD)  132.5 (40.6) pg/mL], respectively. The differ-
ence was statistically insignificant (P  0.780). Similarly,
IL-18 levels were comparable between patients with variable
severity grades during stability. Children with mild persistent
asthma had levels that ranged from 156 to 320 pg/mL
[median  250 pg/mL; mean (SD)  24.9 (65.7) pg/mL].
The corresponding levels of children with moderate persistent
and severe persistent asthma ranged between 125 and 370
pg/mL [median  250 pg/mL; mean (SD)  247.5 (60.4)
pg/mL] and between 100 and 335 pg/mL [median  197.5
pg/mL; mean (SD) 207.5 (96.7) pg/mL], respectively (P
0.485).
The patients’ IL-18 levels were not influenced by the
family history of atopy, inhalation corticosteroid therapy, or
serum total IgE expression whether during asthma exacerba-
tion or during stability. It is worth noting that only 6 (24%)
asthmatic children in our series had normal serum total IgE
concentration. Out of the 25 asthmatic children studied, 17
were considered passive smokers as a result of their exposure
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to tobacco smoke from household contact. Their serum IL-18
expression was comparable to that of the 8 asthmatic children
who did not report exposure to tobacco smoke inside their
homes. The same observation was made among the children
in the control group, of whom 21 out of 35 were passive
smokers (Table 1). The serum IL-18 expression did not
correlate with the age, weight, and height percentiles, dura-
tion of asthma, hemoglobin concentration, or total leukocyte,
FIGURE 1.
FIGURE 2.
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eosinophil, neutrophil, lymphocyte, and monocyte counts of
the patients.
The drop in IL-18 values () between exacerbation and
remission could not be correlated by Spearman correlation
coefficient to age (P  0.58), serum total IgE (P  0.87),
duration of exacerbation (P  0.94), absolute eosinophil
count (P  0.29), or other blood cell counts. Also, a multiple
linear regression analysis could not relate the  values to the
serum total IgE (P  0.49), passive smoking (P  0.78),
duration into exacerbation (P  0.08), or blood cell counts.
However, the drop in IL-18 was positively related to the age
of the patients by regression analysis (P  0.027). The
severity of exacerbation did not significantly affect the mag-
nitude of drop when evaluated by Kruskal-Wallis multivari-
ate analysis (3.425; P  0.18).
The duration since onset of exacerbation at the time of
initial sampling ranged between 4 and 26 hours [median 10
hours; mean (SD)  11.2 (6.2) hours]. The duration of
exacerbation was negatively correlated to the eosinophil
count of patients (r  0.53; P  0.007) but to none of the
other studied clinical or laboratory parameters.
DISCUSSION
Serum IL-18 was underexpressed in a group of children
with bronchial asthma in comparison with that of a matched
group of normal children. After subsidence of exacerbation,
serum IL-18 levels increased significantly but were still lower
than the control values. This comes in accordance with
Cebeci et al17 who reported significantly low serum IL-18
levels in children with acute asthma (median  8.55 pg/mL)
compared with those of a group of controls (median 140.10
pg/mL). Another investigation that sought to evaluate its
expression in bronchoalveolar lavage fluid (BAL) and super-
natant of lipopolysaccharide-stimulated alveolar macro-
phages in adults with bronchial asthma revealed a marked
decrease of IL-18 and suggested that inherently low levels of
IL-18 may be associated with the pathogenesis of asthmatic
airway inflammation. IL-18 may be implicated at an early
stage of the pathogenesis of the disease, and the downstream
effect of this deficiency interacts with other mediators to
modulate disease severity.18 There is evidence that the role of
IL-18 in development of a critical Th1 response occurs early
in this response.19 IL-18 might hypothetically be consumed in
the process of allergic inflammation. Cameron et al20 dem-
onstrated that IL-18 is constitutively expressed in the airway
epithelium and parenchyma of murine lung tissue and human
bronchial biopsies and that its expression is increased under
conditions characterized by Th1 cytokine expression such as
lipopolysaccharide stimulation and pulmonary sarcoidosis
and reduced during Th2 cytokine-mediated conditions such
as ovalbumin challenge and asthma.
In contrast, a study of 370 schoolchildren aged 9 to 10
years living in urban Japanese areas revealed that serum
IL-18 levels were significantly higher in children who had
asthma, allergic rhinitis, or atopic eczema than in the rest of
the enrolled children.21 The same was observed during
asthma exacerbation and convalescence in 34 Chinese chil-
dren.22 Another investigation observed that plasma IL-18,
IL-I2, IL-10, and IL-13 levels were significantly higher in
allergic asthmatic patients than in normal control subjects.23
They explained the excessive IL-18 production by the eleva-
tion of IL-12 levels. El-Mezzein et al4 found no significant
difference in plasma IL-18 concentration between a group of
adult asthmatics and nonallergic controls despite its elevation
in the supernatant fluid of lipopolysaccharide-stimulated pe-
ripheral blood mononuclear cells (PBMC) in the former
group. However, the spontaneous secretion of IL-18 by un-
stimulated PBMC was very low or immeasurable, and mature
form IL-18 was not present in lysates of unstimulated PBMC
from asthmatic patients and nonallergic controls. IL-18 con-
centration was recently reported to be increased in the BAL
fluid, but not in the nasal lavage fluid, in a mouse model of
allergic rhinitis.24
In the current study, a positive correlation was observed
between serum IL-18 values during and after subsidence of
exacerbation—meaning that the lower the IL-18 became
during exacerbation, the lower it remained after quiescence.
This observation probably reflects the persistence of airway
inflammation during stability. Serum IL-18 expression or
magnitude of drop at quiescence was not influenced by sex,
or body size as determined by weight and height percentile
values. The degree of drop () was positively related to age.
The finding is however limited by the sample size.
Serum IL-18 expression did not vary with the degree of
asthma severity whether during exacerbation or stability.
Also, the degree of drop in IL-18 between exacerbation and
remission did not correlate with exacerbation severity. It








Elevated 125 (56) 250 (80)
Normal 140 (91.75) 252.5 (134.75)
z 0.578 0.483
p 0.598 0.642
Family History of Allergy
Positive 125 (56) 250 (109)




Positive 125 (62) 250 (75)




Positive 100 (71) 250 (67.5)
Negative 153 (62.5) 265 (114.5)
z 1.88 0.825
p 0.066 0.44
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seems that IL-18 expression is related to the airway inflam-
matory processes in persistent bronchial asthma irrespective
of clinical severity and it is well known that even patients
with mild persistent asthma may have ongoing allergic in-
flammation in their airways throughout the disease course
including the periods of quiescence of symptoms.
Passive smoking did not influence the serum IL-18
expression or magnitude of drop in our series. However, most
children belonged to the passive smoker category, which
might have influenced this observation. McKay et al25 re-
ported that cigarette smokers had significantly reduced spu-
tum IL-18 mRNA expression compared with nonsmokers.
This effect was more pronounced in asthmatics than in
normal subjects. Such observation may partly offer an expla-
nation for the reduced IL-18 expression in our investigation
given the high levels of environmental tobacco smoke expo-
sure in some developing countries including Egypt.
Serum IL-18 levels in our series did not vary with the
peripheral blood eosinophil count. A relevant study reported
that IL-18 and IL-12 inhibit antigen-induced airway hyper-
responsiveness, lung eosinophilia, and serum IgE, but IL-18
or IL-12 alone failed to modulate any of these allergic
responses.26 However, several investigations showed that in
vivo IL-18 administration alone enhanced allergen-induced
eosinophilic recruitment to the lungs, Th2 cytokine, and IgE
production in sensitized mice.27,28 IL-18 deficiency thus ap-
pears to promote allergic inflammation characterized by eo-
sinophilia.26,29 The latter data, however, are not unchal-
lenged.18 Hence, IL-18 is likely to have different functions,
possibly dependent on where and when it is produced.30 The
combination of IL-2 and IL-18 was recently found to prevent
airway hyperresponsiveness and airway inflammation in a
mouse model, likely through IL-12-mediated induction of
IFN- production in NK cells.31 Intraperitoneal administra-
tion of recombinant IL-18 reduced these antigen-induced
changes in association with a decrease in IL-4 in BAL fluid
and lung tissue. However, it did not affect the IFN- level and
somewhat enhanced the production of IL-5.29
Serum IL-18 expression or degree of drop between
exacerbation and quiescence of symptoms and signs could
not be related to the family history of atopy or serum total IgE
concentration. It is possible that the change in IL-18 expres-
sion reflects the inflammatory process regardless of the atopy
status or IgE levels. Accordingly, a recent study indicated that
serum IL-18 levels were associated with allergic symptoms in
children, independent of serum IgE levels.21 Also, sputum
IL-18 did not correlate with serum IgE levels in a study of
adult asthmatics.25 However, in vitro IL-18 secretion by
lipopolysaccharide-stimulated PBMC was positively corre-
lated to the plasma IgE concentration.4 Administration of
IL-18 alone significantly increased the IgE level production
in vivo by stimulated PBMC in nonsensitized mice, and the
administration of IL-18 and IL-12 induced a 70-fold higher
serum level of IgE.32 The contradiction needs further wider
scale studies for verification.
We did not find an influence for the low-dose inhaled
corticosteroids (ICS) used before enrollment (100–250 g of
fluticasone propionate per day) on serum IL-18 expression.
Increased IL-18 concentrations decreased after steroid treat-
ment in a mouse model.24 A study on humans reported that
patients with bronchial asthma receiving ICS had reduced
levels of IL-18 in BAL fluid irrespective of the dose they
were receiving. The authors, however, stated that the effect of
corticosteroids on IL-18 is currently uncertain because the
sample with the highest level of IL-18 in their series came
from a patient with asthma who was receiving 7 mg of
prednisolone continuously (in addition to 800 g/day of
inhaled budesonide). In that instance, high doses of inhaled
and systemic corticosteroid did not cause any hypothetical
corticosteroid suppression of IL-18 synthesis.18
The time elapsed from the start of exacerbation untill
initial sampling did not influence the serum IL-18 expression
or magnitude of drop at the time of second sampling. How-
ever, a weak negative correlation could link the duration of
exacerbation to the eosinophil count at enrollment. None of
the other clinical or laboratory data of the patients were
significantly related to the spread of time into exacerbation
within the study group.
Manipulation of IL-18 levels may prove of value in
many allergic and nonallergic disorders through modulation
of inflammation, but its influence on other mediators such as
IFN- should be kept in mind before conducting clinical trials
on experimental animals or human beings. It was suggested
that antioxidants may reduce IL-18 expression in asthma by
inhibiting the activity of NF-B.11
The study has certain limitations for credibility. First,
the sample size is too small for solid conclusions to be
formed. Second, for one to objectively study the effect of ICS
on serum IL-18 expression, a prospective study design is
needed in which a group of steroid-naive subjects are tested
before and after a reasonable period of regular ICS therapy.
Finally, the heterogeneity of the patient population may place
constraints on the conclusions.
From our data, it seems that serum IL-18 is underex-
pressed in childhood asthma probably because of consump-
tion at an early stage of asthma pathogenesis. Wider scale
studies are indicated to verify the alterations in IL-18 levels
according to the different protocols of asthma therapy. Given
the complexity of the mechanisms of IL-18 actions in the
airway, further evaluation of its exact biologic significance in
the asthmatic inflammatory process is needed.
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